Hologic (NASDAQ:HOLX) Price Target Raised to $80.00

Hologic (NASDAQ:HOLX) had its price target increased by SVB Leerink from $66.00 to $80.00 in a research report report published on Thursday, BenzingaRatingsTable reports. SVB Leerink currently has an outperform rating on the medical equipment provider’s stock.

HOLX has been the topic of several other research reports. William Blair reissued an outperform rating on shares of Hologic in a research report on Monday, July 27th. TheStreet raised shares of Hologic from a c+ rating to a b- rating in a report on Thursday, May 14th. BTIG Research reaffirmed a buy rating and issued a $84.00 target price (up previously from $63.00) on shares of Hologic in a report on Wednesday. Stifel Nicolaus reduced their target price on shares of Hologic from $52.00 to $45.00 and set a hold rating on the stock in a report on Wednesday, April 8th. Finally, BidaskClub raised shares of Hologic from a sell rating to a hold rating in a report on Wednesday, June 24th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $65.38.

HOLX stock traded up $0.07 during mid-day trading on Thursday, hitting $69.78. 2,584,378 shares of the company were exchanged, compared to its average volume of 1,982,671. The company has a quick ratio of 1.04, a current ratio of 1.47 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $18.07 billion, a P/E ratio of 28.25, a PEG ratio of 3.69 and a beta of 1.47. The business has a fifty day simple moving average of $57.42 and a 200-day simple moving average of $50.06. Hologic has a 12-month low of $26.49 and a 12-month high of $70.35.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.37. The company had revenue of $822.90 million during the quarter, compared to analyst estimates of $622.96 million. Hologic had a net margin of 20.03% and a return on equity of 31.40%. Hologic’s revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. Research analysts predict that Hologic will post 2.42 EPS for the current year.

In other news, CEO Stephen P. Macmillan sold 190,996 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total transaction of $9,735,066.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Peter J. Valenti III sold 10,493 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $51.82, for a total transaction of $543,747.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 243,932 shares of company stock worth $12,507,250. 1.00% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Comerica Bank grew its position in shares of Hologic by 2.3% during the second quarter. Comerica Bank now owns 49,532 shares of the medical equipment provider’s stock worth $3,079,000 after acquiring an additional 1,111 shares during the last quarter. Signaturefd LLC grew its position in Hologic by 37.8% in the 2nd quarter. Signaturefd LLC now owns 1,091 shares of the medical equipment provider’s stock valued at $62,000 after buying an additional 299 shares during the last quarter. Chartwell Investment Partners LLC purchased a new position in Hologic in the 2nd quarter valued at $1,006,000. State of Michigan Retirement System grew its position in Hologic by 7.3% in the 2nd quarter. State of Michigan Retirement System now owns 65,920 shares of the medical equipment provider’s stock valued at $3,757,000 after buying an additional 4,460 shares during the last quarter. Finally, Duality Advisers LP purchased a new position in Hologic in the 2nd quarter valued at $331,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Accumulation/Distribution

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.